Virtual Microscope Images at your Fingertips
Researchers and educators are now able to access their entire library of virtual microscope images with just a tap of the finger on the OlyVIA Mobile iPad App.
Free to download from the iTunes App Store, the app is designed for images captured with the Olympus VS120 virtual slide scanning system. Images shared via the Olympus Net Image ServerSQL v.2.7 software can now be conveniently accessed from anywhere in the world using the iPad. In addition to VS120 images, any images captured in or converted to the .vsi file format, including images from cellSens software, are uploadable for remote viewing on an iPad.
With a click, tap or finger pinch, users can verify, select, pan, zoom and observe their virtual images at different magnifications. The OlyVIA Mobile App makes the most of both the familiar user-friendliness and portability of the iPad, combined with the excellent image quality of the Olympus VS120 system to provide an insightful user experience. Users who download the free app will also have access to a library of high quality virtual slide images that can be used for demonstration or educational purposes.
The modular Olympus VS120 virtual slide system creates high-resolution digital images of complete microscope specimens that can be stored on a server for simultaneous remote viewing, at a range of magnifications. The system is optimised to provide outstanding brightfield and fluorescence performance, combined with precise colour rendition and scanning. The VS120 earned three First Place awards at the biennial International Scanner Contest (ISC) in 2012, claiming victory in the important categories of Colour and Precision, Fluorescence 20x and Fluorescence 40x. The system also won two awards at the inaugural contest in 2010.
For more information on the Olympus OlyVIA Mobile iPad app, please visit www.olympus-europa.com/microscopy, or download OlyVIA Mobile from the App Store on iTunes.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.